New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
07:19 EDTINCYIncyte data positive, says Oppenheimer
After Incyte reported results for ruxolitinib in pancreatic cancer, Oppenheimer thinks the data supports the evaluation of ruxolitinib in a wide range of tumor types. Following the results of an IDO + ipilimumab proof-of-concept study in melanoma, Oppenheimer finds the results encouraging. The firm keeps a $75 price target on the shares and reiterates an Outperform rating.
News For INCY From The Last 14 Days
Check below for free stories on INCY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for INCY

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use